uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Sundberg, Åsa Liljegren
Alternative names
Publications (2 of 2) Show all publications
Nordberg, E., Steffen, A.-C., Persson, M., Sundberg, Å. L., Carlsson, J. & Glimelius, B. (2005). Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor.. European Journal of Nuclear Medicine and Molecular Imaging, 32(7), 771-7
Open this publication in new window or tab >>Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor.
Show others...
2005 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 32, no 7, p. 771-7Article in journal (Refereed) Published
Abstract [en]

PURPOSE: The purpose of this study was to analyse whether non-radiolabelled epidermal growth factor (EGF) can modify the cellular uptake of 125I when delivered as [125I]trastuzumab. 125I was used as a marker for the diagnostically and therapeutically more interesting isotopes 123I (SPECT), 124I (PET) and 131I (therapy). METHODS: The cell-associated radioactivity was measured in squamous carcinoma A431 cells following addition of [125I]trastuzumab. Different concentrations of [125I]trastuzumab and unlabelled EGF were used, and the total, membrane-bound and internalised radioactivity was measured. We also analysed how EGF and trastuzumab affected the cell growth. RESULTS: It was generally found that the cellular 125I uptake was decreased by the addition of EGF when [125I]trastuzumab was added for short incubation times. However, if the incubation times were longer, EGF increased the 125I uptake. This shift came earlier when higher [125I]trastuzumab concentrations were applied. The addition of EGF also influenced cell proliferation, and concentrations above 10 ng/ml reduced cell growth by approximately 20% after 24 h of incubation. CONCLUSION: By adding unlabelled EGF, it was possible to modify the cellular uptake of [125I]trastuzumab. This points towards new approaches for the modification of radionuclide uptake in EGFR- and HER2-positive tumours.

Keywords
Antibodies; Monoclonal/*administration & dosage/chemistry, Antineoplastic Agents/*administration & dosage, Cell Line; Tumor, Cell Membrane/metabolism, Cell Proliferation, Dose-Response Relationship; Drug, Epidermal Growth Factor/*administration & dosage/metabolism, Humans, Iodine Radioisotopes/*pharmacokinetics, Ligands, Positron-Emission Tomography, Receptor; Epidermal Growth Factor/metabolism, Receptor; erbB-2/metabolism, Time Factors, Tomography; Emission-Computed; Single-Photon, Tumor Markers; Biological
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:uu:diva-80492 (URN)10.1007/s00259-005-1761-8 (DOI)15765233 (PubMedID)
Available from: 2007-02-12 Created: 2007-02-12 Last updated: 2017-12-14Bibliographically approved
Sundberg, Å. L., Gedda, L., Orlova, A., Bruskin, A., Blomquist, E., Carlsson, J. & Tolmachev, V. (2004). [177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma. Cancer Biotherapy and Radiopharmaceuticals, 19(2), 195-204
Open this publication in new window or tab >>[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma
Show others...
2004 (English)In: Cancer Biotherapy and Radiopharmaceuticals, ISSN 1084-9785, E-ISSN 1557-8852, Vol. 19, no 2, p. 195-204Article in journal (Refereed) Published
Abstract [en]

Patients with glioblastoma multiforme have a poor prognosis due to recurrences originating from spread cells. The use of radionuclide targeting might increase the chance of inactivating single tumor cells with minimal damage to surrounding healthy tissue. As a target, overexpressed epidermal growth factor receptors (EGFR) may be used. A natural ligand to EGFR, the epidermal growth factor (EGF) is an attractive targeting agent due to its low molecular weight (6 kDa) and high affinity for EGFR. 177Lu (T(1/2) = 6.7 days) is a radionuclide well suited for treatment of small tumor cell clusters, since it emits relatively low-energy beta particles. The goal of this study was to prepare and preclinically evaluate both in vitro and in vivo the [177Lu]Bz-DTPA-EGF conjugate. The conjugate was characterized in vitro for its cell-binding properties, and in vivo for its pharmacokinetics and ability to target EGFR. [177Lu]Bz-DTPA-EGF bound to cultured U343 glioblastoma cells with an affinity of 1.9 nM. Interaction with EGFR led to rapid internalization, and more than 70% of the cell-associated radioactivity was internalized after 30 minutes of incubation. The retention of radioactivity was good, with more than 65% of the 177Lu still cell-associated after 2 days. Biodistribution studies of i.v. injected [177Lu]Bz-DTPA-EGF in NMRI mice demonstrated a rapid blood clearance. Most of the radioactivity was found in the liver and kidneys. The liver uptake was receptor-mediated, since it could be significantly reduced by preinjection of unlabeled EGF. In conclusion, [177Lu]Bz-DTPA-EGF seems to be a promising candidate for locoregional treatment of glioblastoma due to its high binding affinity, low molecular weight, and ability to target EGFR in vivo.

Keywords
Animals, Cell Line; Tumor, Chelating Agents/chemistry/pharmacokinetics, Drug Evaluation; Preclinical, Epidermal Growth Factor/chemistry/pharmacokinetics/*therapeutic use, Glioblastoma/*radiotherapy, Humans, Lutetium/chemistry/pharmacokinetics/*therapeutic use, Mice, Mice; Inbred Strains, Pentetic Acid/chemistry/pharmacokinetics, Protein Binding, Radioisotopes/chemistry/pharmacokinetics/*therapeutic use, Radiopharmaceuticals/chemical synthesis/chemistry/pharmacokinetics/*therapeutic use, Research Support; Non-U.S. Gov't, Sensitivity and Specificity, Tissue Distribution
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-72884 (URN)10.1089/108497804323071977 (DOI)15186600 (PubMedID)
Available from: 2005-05-30 Created: 2005-05-30 Last updated: 2017-12-14Bibliographically approved
Organisations

Search in DiVA

Show all publications